- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Cilta-cel, Cyclophosphamide, Fludarabine
- Drug
- Lead sponsor
- Stichting European Myeloma Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 759 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2040
- U.S. locations
- 27
- States / cities
- Little Rock, Arkansas • Duarte, California • San Diego, California + 21 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 50
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Liver Cancer, Rhabdomyosarcoma, Malignant Rhabdoid Tumor, Liposarcoma, Wilms Tumor, Yolk Sac Tumor
- Interventions
- AGAR T cells
- Genetic
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2040
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
- Interventions
- CARv3-TEAM-E T cells
- Drug
- Lead sponsor
- Marcela V. Maus, M.D.,Ph.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Sarcoma, HER-2 Protein Overexpression, Osteosarcoma, Rhabdomyosarcoma, Ewing Sarcoma, Synovial Sarcoma, Soft Tissue Sarcoma, Undifferentiated Sarcoma
- Interventions
- T cells or CAR T cells, Pembrolizumab Injectable Product, Nivolumab Injectable Product
- Genetic · Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 1 Year to 25 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2043
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma, Myeloma, Leukemia
- Interventions
- Kappa CD28 T cells
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2035
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Lymphomas
- Interventions
- Anti-CD30 CAR T cells
- Genetic
- Lead sponsor
- Peking University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
- Interventions
- CD30.CAR-T
- Drug
- Lead sponsor
- Tessa Therapeutics
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2036
- U.S. locations
- 4
- States / cities
- Duarte, California • Nashville, Tennessee • Houston, Texas
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- EGFRvIII CAR T cells
- Biological
- Lead sponsor
- Daniel Landi
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Generalized Myasthenia Gravis (gMG)
- Interventions
- CABA-201
- Biological
- Lead sponsor
- Cabaletta Bio
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 17
- States / cities
- Orange, California • Sacramento, California • San Francisco, California + 12 more
- Conditions
- Osteosarcoma, Neuroblastoma
- Interventions
- GD2 T cells, VZV vaccine, Fludarabine, Cyclophosphamide
- Genetic · Biological · Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Not listed
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2034
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Liver Cell Carcinoma, Solid Tumor, Wilms Tumor, Malignant Rhabdoid Tumor, Yolk Sac Tumor, Rhabdomyosarcoma, Liposarcoma, Embryonal Sarcoma of the Liver
- Interventions
- CATCH T cells
- Genetic
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2040
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pancreatic Cancer
- Interventions
- CART-meso-19 T cells, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Malignant Brain Neoplasm, Recurrent Malignant Brain Neoplasm, Refractory Malignant Brain Neoplasm
- Interventions
- Cyclophosphamide, Fludarabine, IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
- Drug · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 4 Years to 25 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 3
- States / cities
- Duarte, California • Los Angeles, California • Ann Arbor, Michigan
- Conditions
- Acute Myeloid Leukemia
- Interventions
- CD4CAR
- Biological
- Lead sponsor
- Huda Salman
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2042
- U.S. locations
- 4
- States / cities
- Miami, Florida • Indianapolis, Indiana • Houston, Texas
- Conditions
- T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
- Interventions
- CD7.CAR/28zeta CAR T cells
- Genetic
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 75 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2041
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143, Cyclophosphamide, Fludarabine, Leukapheresis
- Biological · Drug · Procedure
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Multiple Myeloma
- Interventions
- Anitocabtagene Autoleucel, Cyclophosphamide, Fludarabine, Pomalidomide, Bortezomib, Dexamethasone, Daratumumab, Carfilzomib
- Drug
- Lead sponsor
- Kite, A Gilead Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 46
- States / cities
- Gilbert, Arizona • Duarte, California • Los Angeles, California + 35 more
- Conditions
- Pediatric Solid Tumor, Neuroblastoma
- Interventions
- B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Robbie Majzner
- Other
- Eligibility
- 9 Months to 30 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- MuSK Myasthenia Gravis
- Interventions
- MuSK-CAART
- Biological
- Lead sponsor
- Cabaletta Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 5
- States / cities
- Orange, California • Sacramento, California • Kansas City, Kansas + 2 more
- Conditions
- CD19 Positive, CD22 Positive, Minimal Residual Disease, Progressive Disease, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Non-Hodgkin Lymphoma
- Interventions
- Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 6 Months to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Light Chain (AL) Amyloidosis
- Interventions
- NXC-201 CAR-T
- Biological
- Lead sponsor
- Nexcella Inc.
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2039
- U.S. locations
- 18
- States / cities
- Berkeley, California • Duarte, California • Los Angeles, California + 14 more
- Conditions
- Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland, Lung Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Solid Tumor
- Interventions
- CAdVEC
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2038
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Metastatic Breast Cancer, Triple Negative Breast Cancer
- Interventions
- cMet RNA CAR T cells
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges, Breast Cancer, HER2-positive Breast Cancer
- Interventions
- Chimeric Antigen Receptor T-Cell Therapy
- Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California